Prism 302-A Three-Part, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self Administered by Adults with Phenylketonuria

Grants and Contracts Details

StatusFinished
Effective start/end date6/19/142/12/20

Funding

  • BioMarin Pharma Inc: $914,348.00